This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Bileaflet mechanical heartvalves (MHV) remain a viable option for aorticvalve replacement, particularly for younger patients and patients from low- and middle-income countries and underserved communities. Despite their exceptional durability, MHV recipients are at increased risk of thromboembolic complications.
Aortic stenosis is a narrowing of the aorticvalve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1.
IntroductionClinical evidence highlighting the efficacy and safety of transcatheter aorticvalve replacement (TAVR) and the 2019 Food and Drug Administration (FDA) approval for TAVR in low-risk (younger) patients has created a demand for durable and long-lasting bioprosthetic heartvalve (BHV) leaflet materials.
Photo courtesy of Mount Sinai Health System milla1cf Thu, 02/22/2024 - 13:47 February 22, 2024 — Ismail El-Hamamsy , MD, PhD, Director of Aortic Surgery for the Mount Sinai Health System and the Mount Sinai Randall B.
A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heartvalve disease -- aortic stenosis (AS).
Recently published research shows a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aorticvalve replacement, a type of heartvalve operation.
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heartvalves (SEV).
A large population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heartvalve disease—aortic stenosis (AS).
Small aortic annulus poses a major challenge in aorticvalve replacement due to the increased risk of prosthesispatient mismatch (PPM) and increased surgical risk. In recent years, transcatheter aorticvalve replacement (TAVR) has emerged as a popular alternative to the traditional surgical aorticvalve replacement.
Getty Images milla1cf Fri, 06/07/2024 - 15:10 June 7, 2024 — Calcific aorticvalve disease (CAVD) is the major heartvalve disease that afflicts nearly 10 million patients globally with an annual mortality exceeding 100,000, and the numbers continue to rise.
The global, randomized trial ( envisiontrial.com ) will evaluate the safety and effectiveness of Abbott’s minimally invasive Navitor transcatheter aorticvalve implantation (TAVI) system in approximately 1,500 patients at intermediate or low surgical risk with severe aortic stenosis (narrowing of the aorticvalve).
Dr. Shettys team followed 252 patients who underwent the Ross procedure, a heartvalve replacement operation commonly used to treat younger patients with severe aorticvalve disease. Freedom from aortic regurgitation was 95.1%, 92.2%, 87.7%, and 84.5% Shettys team found that survival rates were 95.8% at 20 years.
Aortic stenosis is a narrowing of the aorticvalve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1.
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aorticvalve replacement was the primary treatment option for severe AS for decades.
(MedPage Today) -- Operators reported the initial success of a novel transcatheter technique for treating complex paravalvular leaks (PVLs) after transcatheter aorticvalve replacement (TAVR) or transcatheter mitral valve replacement (TMVR) in.
The HeartValve Collaboratory has proposed a framework to standardize best practices for using multimodality imaging in transcatheter valve failure (TVF) following transcatheter aorticvalve replacement (TAVR), in a State-of-the-Art Review.
The co-occurrence of a bicuspid aorticvalve (BAV) with TSC is exceedingly rare.Case summaryWe report the case of a 26-year-old woman with genetically confirmed TSC, harboring a novel pathogenic variant in the TSC2 gene. multi-system characteristics of TSC were also presented, affecting skin, brain, lung, kidney, and bone.
In all cases, patients achieved complete resolution of aortic disease with no residual stenosis or regurgitation immediately following the procedure, and all patients were discharged within 24-48 hours of the procedure.
Recent findings from a study on a transcatheter heartvalve (THV) system, which includes a new class of transcatheter aorticvalve, showed positive results in the device's ability to function as a healthy and natural aorticvalve in patients with aortic stenosis (AS).
Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aorticvalve replacement (TAVR) as the initial intervention may be appealing to many. If their transcatheter heartvalve degenerates later in life, most will hope to undergo redo-TAVR.
Highlights include: Due to the aging population and improvement in diagnostic strategies, the prevalence of heartvalve disease is expected to double by 2040 and triple by 2060.As As a result, it is estimated that the number of patients requiring heartvalve interventions will increase significantly in the coming decades.
The program directors have chosen an ambitious theme of "The Taming of the AorticValves," inspired by Shakespeare's classic The Taming of the Shrew. There will also be an in-depth discussion on the lifelong management of aorticvalve surgery patients.
The conference theme is “Goldilocks: Toward the Optimal Mitral Valve,” and the organizers aim to bring together distinguished experts from around the world to share their knowledge and engage in academic discussions on the latest trends in treatments related to aorticvalve disease. Details coming soon!
Nature Reviews Cardiology, Published online: 27 June 2024; doi:10.1038/s41569-024-01059-1 Preliminary experience with the use of transcatheter aorticvalve implantation (TAVI) to treat non-calcific aortic regurgitation has raised concerns about the short-term effectiveness of TAVI in this setting.
Background Aortic regurgitation with dilated annulus presents a technical challenge for conventional transcatheter aorticvalve implantation (TAVI) procedures. The patient recovered well post-operatively with good hemodynamic resolution.
Objectives To describe the occurrence of significant pericardial effusion, and to investigate characteristics associated with pericardial effusion within three months following heartvalve surgery. Data were gathered from The Western Denmark Heart Registry and electronic patient records. Being a man (HR 2.30, 95% CI 1.32
Background Cardiovascular MRI is advantageous in transcatheter aorticvalve implantation (TAVI) planning. Methods Thirty patients with severe aortic stenosis were prospectively enrolled. Transcatheter heartvalve (THV) sizing was performed based on CCTA measurements and compared with 3D whole-heart MRI measurements.
mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. JenaValve presented positive results of its U.S.
milla1cf Tue, 04/23/2024 - 15:53 April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management.
Getty Images milla1cf Thu, 06/13/2024 - 20:38 June 13, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. More specifically, the Avalus Ultra surgical valve has: A low valve profile designed to facilitate ease of use at implant.1,2
We are blessed with 4 heartvalves – 2 on the left side which are known as the mitral and aorticvalves and 2 on the right side – the tricuspid and pulmonary valves. If the patient is not symptomatic but if we see that the heart is beginning to weaken then again the valve needs fixing.
The goal of the LANDMARK trial was to evaluate transcatheter aorticvalve replacement (TAVR) with the Myval prosthesis compared with a contemporary prosthesis among patients with symptomatic severe aortic stenosis.
Isaac George , Surgical Director of the HeartValve Center. Left Ventricular Rapid Pacing Via the Valve Delivery Guidewire in Transcatheter AorticValve Replacement. JACC Cardiovasc Interv. 2019 Dec 23;12(24):2449-2459. If you enjoy this content, please share it with a colleague
Transcatheter aorticvalve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heartvalves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis.
What are the outcomes with transfemoral transcatheter aorticvalve implantation (TAVI) in patients with pure aortic regurgitation (AR) using the Trilogy transcatheter heartvalve?
BACKGROUND:Data concerning the outcomes of transcatheter aorticvalve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. Self-expanding transcatheter heartvalves were used in the majority of patients (n=1160; 91.4%). In the matched population, differences in mortality (30 days: 4.2% 2.44];P=0.035).
BACKGROUND:Transcatheter heartvalve (THV) underexpansion after transcatheter aorticvalve replacement may be associated with worse outcomes. Circulation: Cardiovascular Interventions, Ahead of Print.
reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter AorticValve Replacement (TAVR). milla1cf Tue, 12/26/2023 - 21:36 December 26, 2023 — MindMics, Inc. the R&D Manager of MindMics.
As the population ages and treatment options for heartvalve disease increase, the number of patients with intracardiac valve prostheses is growing rapidly. Mechanical valve prostheses carry the highest (and persistent) risk of thromboembolism, and these patients require anticoagulation with vitamin K antagonists (warfarin).
In this scientific statement, we review the basic cellular structures of the human heartvalves and discuss how these structures change in primary valvular heart disease.
Introduction Severe aortic stenosis is a major cause of morbidity and mortality. The existing treatment pathway for transcatheter aorticvalve implantation (TAVI) traditionally relies on tertiary HeartValve Centre workup. Methods The centre performing local workup implemented a novel TAVI referral pathway.
Transcatheter mitral valve-in-ring (MViR) using third-generation balloon-expandable aortic transcatheter heartvalves was associated with a significant reduction in mitral regurgitation (MR) and improvement in heart failure symptoms at one year, with the tradeoff of elevated valvular gradients and a high rate of reintervention, according to a recent (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content